I really think companies should develop their drugs in a way that would allow them to by-pass a lengthy Phase 3 trial, similar to what Ariad is doing with Ponatinib. Clearly Pona is a unique example. Problem is, a lot of development companies are borderline scams that are just ATM machines for Executives and Board Members so their Phase 1 trials are complete nonsense, instead of a true Phase 1/2.
I read a really good abstract not too long ago re: avoiding Phase 3 trials by designing better focused trials based on personaized medicine. ...which would hopefully speed up the nonsense of taking 15 years to get a drug from lab to marketing approval.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.